NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.
Dr. James Bradner
Novartis Institutes for BioMedical Research Appoints President
Dr. James (Jay) Bradner, physician-scientist from Dana-Farber Cancer Institute and Harvard Medical School, has been appointed president of the Novartis Institutes for BioMedical Research (NIBR) and a member of the executive committee of Novartis, effective March 1, 2016.
Dr. Bradner succeeds Mark Fishman, M.D., who will reach his contractual retirement age in March 2016 after a distinguished 13-year career at Novartis as the leader of the company’s drug discovery and early clinical development efforts.
Dr. Bradner is on the faculty of Harvard Medical School in the Department of Medical Oncology at the Dana-Farber Cancer Institute. He is a graduate of Harvard College and the University of Chicago Medical School. He did his residency in medicine at the Brigham & Women’s Hospital, as well as fellowship in medical oncology and hematology at the Dana-Farber Cancer Institute, where he has been on the faculty since 2005. Dr. Bradner has co-authored more than 130 scientific publications and 30 U.S. patent applications.
Bayer Appoints Head of U.S. Pharmaceuticals Business
Bayer appoints Habib Dable as president of Bayer HealthCare Pharmaceuticals, the U.S.-based division of the global company’s pharmaceutical business. Mr. Dable reports to Philip Blake, who has assumed the role of head of region Americas for Bayer HealthCare Pharmaceuticals and continues leading U.S. corporate functions as senior Bayer representative (SBR) in the United States, a position he has held since 2012.
Previously, Mr. Dable was global head of specialty medicine for Bayer HealthCare Pharmaceuticals, a role he held since 2013 and in which he was responsible for overseeing four therapeutic areas for the company — hematology, oncology, ophthalmology, and neurology. He began his career at Bayer in 1994 as a sales representative and moved on to hold a number of senior roles in Canada, Japan, and the United States, focusing on strategic planning, sales management, and global product marketing including successfully leading global product launches. Mr. Dable earned a master’s of business administration degree from the University of New Brunswick in Canada.
Dr. Jeffrey Lawson
Humacyte Appoints Chief
Humacyte, an innovator in biotechnology and vascular regenerative medicine, has appointed American Board of Surgery certified surgeon Jeffrey Lawson, M.D., Ph.D., as chief medical officer. Dr. Lawson, a clinical advisor to Humacyte over the past 10 years, oversees the medical and clinical development of the company’s products.
Dr. Lawson recently served in various leadership roles at Duke University Medical Center. After receiving his doctorate in medicine from the University of Vermont College of Medicine in 1991 and his Ph.D. in cell and molecular biology from the same institution, Dr. Lawson completed his residency in general and thoracic surgery in 1999 at Duke University Medical Center. In 2002, he completed a fellowship in vascular surgery, also at Duke University Medical Center.
Rodin Therapeutics Appoints CEO
Rodin Therapeutics, a biotechnology company applying insights from epigenetics to develop novel therapeutics for neurological disorders, has appointed Adam Rosenberg as CEO. Mr. Rosenberg brings almost 20 years of entrepreneurial and transactional leadership, and will also be appointed to Rodin’s board of directors.
Mr. Rosenberg most recently served as co-founder, director and CEO at Teleos Therapeutics, a biotechnology company leveraging unique insights in zebrafish chemical biology. Mr. Rosenberg holds a a JD from the University of Virginia School of Law.
Giant Creative/Strategy, a full-service independent healthcare communications agency, has made several promotions. Vanya Akraboff has been promoted to senior VP, group creative director from VP, group creative director. Ms. Akraboff has responsibility for the creative visionary for multiple accounts, and she has a proven track record of developing work that leads to market success for clients and brands. She has been with Giant since 2003.
Kristine Ellis has been promoted to senior VP, creative director from VP, group creative director. A key leader at Giant, Ms. Ellis works closely with clients and team members to achieve creative and strategic success, while contributing importantly to the culture and future direction of the agency. She has been with the agency since 2006.
Kim Robinson has been promoted to VP, management supervisor from management supervisor. She is an account leader responsible for delivering day-to-day results and strategic insight, as well as ongoing brand stewardship for United States and global business. She joined Giant in June 2012.
Janet Vennari has been promoted to senior VP, managing group director from VP, management supervisor. Ms. Vennari is the business unit lead overseeing multiple healthcare accounts with responsibility for strategically leading clients and account teams, and for generating both organic and new business. She has been with Giant since January 2014.
Makovsky Names Director of
Makovsky, a leading independent integrated communications firm, has promoted Lee Davies, senior VP, to director of client services, health practice.
Mr. Davies is chair of the agency’s flagship Quality Commitment Program, working with teams across practices to ensure quality client work and to identify the best resources to deploy for optimal results for Makovsky clients.
Before joining Makovsky, Mr. Davies was director, global media relations and product communications at Merck. (PV)